Products
Veligrotug Biosimilar Monoclonal Antibody (IGF-1R) for Research
Cat No.: GMP-Bios-INN-1450
Anti-IGF1R/CD221 therapeutic antibody (Pre-made Veligrotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Veligrotug (development codes AVE-1642/VRDN-001) is a chimeric monoclonal antibody targeting IGF-1 receptor (IGF1R). It is developed by ImmunoGen and sanofi-aventis and Viridian Therapeutics and Zenas BioPharma for Graves ophthalmopathy in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1450-1mg | 1mg | 3090 |
| GMP-Bios-INN-1450-10mg | 10mg | |
| GMP-Bios-INN-1450-100mg | 100mg | |
| GMP-Bios-INN-1450-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Veligrotug biosimilar, Whole mAb, Anti-IGF1R/CD221 Antibody: Anti-IGF1R/CD221/Insulin-like growth factor 1 receptor/Insulin-like growth factor I receptor (IGF-I receptor) therapeutic antibody |
| INN Name | Veligrotug |
| Target | IGF1R/CD221 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | ImmunoGen;sanofi-aventis;Viridian Therapeutics;Zenas BioPharma |
| Conditions Approved | na |
| Conditions Active | Graves ophthalmopathy |
| Conditions Discontinued | Breast cancer;Multiple myeloma;Solid tumours |
| Production | na |
| Development Tech | na |
